Milestone payment further bolsters Innate’s cash position
View post:
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca
REGULATED INFORMATION
Read more from the original source:
Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA
Restart of Phase 2 Clinical Trial of Haduvio for Chronic Cough in Patients with IPF
More:
Trevi Therapeutics Provides Clinical Trial Updates for Haduvio™
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that an abstract for the TRIDENT-1 clinical study of its lead drug candidate repotrectinib has been selected for a mini-oral presentation on Jan. 31, 2021 at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer.
Presentations highlight clinical and preclinical progress of long-acting drug candidates for serious fungal and viral infections
See the original post:
Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020
NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced the formation of a Scientific Advisory Board (SAB) including three of the leading global experts in exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
See the original post here:
AzurRx BioPharma Announces Formation of Scientific Advisory Board
NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has entered into a research collaboration and commercial license agreement with ArsenalBio for the use of Teneobio’s UniDabs®, single-domain, human heavy chain only antibodies in Chimeric Antigen Receptor (CAR) T-cell therapy.
Read this article:
Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio